1500 / 1835
Phase III Frontline HL (ECHELON-1)
•
Design
•
Target N=1240
•
Primary outcome measure: Modified progression free survival (mPFS)
Experimental Arm
AVD + B-Vedotin x6 cycles
Standard of Care
ABVD x6 cycles
Newly Diagnosed Advanced
Stage cHL Patients
>18 y
R
Slide adapted from Takeda/Seattle Genetics